Selective C-Reactive Protein-Apheresis in Patients.
Apheresis
C-reactive protein
Immunoadsorption
Myocardial infarction
Journal
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
ISSN: 1744-9987
Titre abrégé: Ther Apher Dial
Pays: Australia
ID NLM: 101181252
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
22
02
2019
revised:
22
03
2019
accepted:
26
03
2019
pubmed:
30
3
2019
medline:
2
5
2020
entrez:
30
3
2019
Statut:
ppublish
Résumé
C-reactive protein (CRP), the prototype human acute-phase protein, is a well-known marker of inflammation. However, CRP may also mediate tissue damage in various human diseases like atherosclerosis, acute myocardial infarction, dilated cardiomyopathy, stroke, and potentially autoimmune disease. Therefore, CRP elimination from human plasma may indeed be a widely usable therapeutic approach. Recently, a first-in-man case report of selective CRP-apheresis in a patient with acute ST-segment elevation myocardial infarction (STEMI) has been published. Here, the method is further elucidated by detailed description of 13 patients receiving CRP-apheresis at two study centers. Thirteen patients received two sequential CRP-apheresis treatments with the PentraSorb CRP adsorber starting 24 ± 12 h after STEMI and successful percutaneous coronary intervention (PCI). CRP was measured immediately before and after each treatment, and additionally twice a day for a period of 96 h after symptom onset. Compared to the initial (before-treatment) CRP plasma concentration, CRP-apheresis resulted in an average 53.4% ± 11.9% CRP depletion. First apheresis was performed 27.5 ± 4.6 h after symptom onset at a mean CRP concentration of 25.1 ± 11.1 mg/L. Mean CRP concentration after the first treatment was 12.1 ± 6.4 mg/L. Second apheresis started 47.9 ± 5.4 h after symptom onset at a mean CRP concentration of 30.2 ± 21.4 mg/L. After the second treatment, mean CRP concentration was reduced to 13.9 ± 10.9 mg/L. No severe apheresis-associated side effects were observed. Patients tolerated selective CRP-apheresis without any side effects. The new method is feasible and safe and significantly reduces CRP plasma concentration in humans.
Identifiants
pubmed: 30924312
doi: 10.1111/1744-9987.12804
doi:
Substances chimiques
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
570-574Subventions
Organisme : Pentracor GmbH
Informations de copyright
© 2019 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.
Références
Kalkman DN, Aquino M, Claessen BE et al. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. Eur Heart J 2018;39:4101-8.
Ridker PM, Everett BM, Thuren T et al., CANTOS Trial Group. Antiinflammatory therapy with Canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119-31.
Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ, CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 2018;391:319-28.
Torzewski J, Torzewski M, Bowyer DE et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 1998;18:1386-92.
Lagrand WK, Niessen HW, Wolbink GJ et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 1997;95:97-103.
Zimmermann O, Bienek-Ziolkowski M, Wolf B et al. Myocardial inflammation and non-ischaemic heart failure: is there a role for C-reactive protein?Basic Res Cardiol 2009;104:591-9.
VanGilder RL, Davidov DM, Stinehart KR et al. C-reactive protein and long-term ischemic stroke prognosis. J Clin Neurosci 2014;21:547-53.
Peisajovich A, Marnell L, Mold C, Du Clos TW. C-reactive protein at the interface between innate immunity and inflammation. Expert Rev Clin Immunol 2008;4:379-90.
Volanakis JE, Kaplan MH. Interaction of C-reactive protein complexes with the complement system. II. Consumption of Guinea pig complement by CRP complexes: requirement for human C1q. J Immunol 1974;113:9-17.
Mortensen RF, Duszkiewicz JA. Mediation of CRP-dependent phagocytosis through mouse macrophage fc-receptors. J Immunol 1977;119:1611-6.
Ries W, Sheriff A, Heigl F, Zimmermann O, Garlichs CD, Torzewski J. "First in man": case report of selective C-reactive protein apheresis in a patient with acute ST segment elevation myocardial infarction. Case Rep Cardiol 2018;2018:4767105.
Mattecka S, Brunner P, Hahnel B, Kunze R, Vogt B, Sheriff A. PentraSorb C-Reactive Protein: characterization of the selective C-reactive protein adsorber resin. Ther Apher Dial 2019. https://doi.org/10.1111/1744-9987.12796.
Sheriff A, Schindler R, Vogt B et al. Selective apheresis of C-reactive protein: a new therapeutic option in myocardial infarction?J Clin Apher 2015;30:15-21.
Dimitrijević O, Stojcevski BD, Ignjatović S, Singh NM. Serial measurements of C-reactive protein after acute myocardial infarction in predicting one-year outcome. Int Heart J 2006;47:833-42.
Stumpf C, Sheriff A, Zimmermann S et al. C-reactive protein levels predict systolic heart failure and outcome in patients with first ST-elevation myocardial infarction treated with coronary angioplasty. Arch Med Sci 2017;13:1086-93.